Systemic complement depletion inhibits experimental cerebral vasospasm

被引:38
作者
German, JW
Gross, CE
Giclas, P
Watral, W
Bednar, MM
机构
[1] UNIV VERMONT, COLL MED, DEPT SURG, DIV NEUROSURG, BURLINGTON, VT 05405 USA
[2] NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA
关键词
complement; rabbit; subarachnoid hemorrhage; vasospasm;
D O I
10.1097/00006123-199607000-00028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: Cerebral vasospasm is the leading cause of morbidity and mortality in patients who are hospitalized because of aneurysmal subarachnoid hemorrhage (SAH). Recent work has suggested that activation of the complement cascade contributes to the development of cerebral vasospasm. To further examine this hypothesis, a rabbit model of SAH was employed. METHODS: Two milliliters of autologous arterial blood was injected into the region of the perimesencephalic cistern. Forty-eight hours after SAH was induced, intravital perfusion-fixation was performed. Morphometric analysis of the basilar artery was used to assess the extent of cerebral vasospasm after pretreatment with the complement depleting agent, cobra venom factor (CVF), or vehicle. Rabbits were randomized to one of four groups: 1) sham (n = 5); 2) sham + CVF (n = 4); 3) SAH (n = 10); or 4) SAH + CVF (n = 7). Twenty-four hours before induction of SAH, the animals received either 100 units/kg CVF or vehicle. The total hemolytic potential of the serum confirmed a significant (P < 0.05) reduction in serum complement activity 24 hours after the administration of CVF. RESULTS: Pretreatment with CVF significantly (P < 0.0083) reduced the extent of vasospasm, as assessed by lumen diameter from 393.9 a 100.1 mu m (mean +/- standard deviation) in the SAH group to 510.7 +/- 72.8 mu m in the SAH + CVF group, when compared with the sham (594.5 +/- 27.9 mu m) and sham + CVF (587.7 +/- 47.3 mu m) groups. CONCLUSION: The results suggest a role for complement activation in SAH.
引用
收藏
页码:141 / 145
页数:5
相关论文
共 32 条
[1]   THE REPARATIVE PROCESSES IN SUBARACHNOID HEMORRHAGE [J].
ALPERS, BJ ;
FORSTER, FM .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1945, 4 (03) :262-268
[2]   THE NATURE AND CLINICAL SIGNIFICANCE OF PIGMENTS IN THE CEREBROSPINAL FLUID [J].
BARROWS, LJ ;
HUNTER, FT ;
BANKER, BQ .
BRAIN, 1955, 78 (01) :59-80
[3]   PREVENTION OF CHRONIC EXPERIMENTAL CEREBRAL VASOSPASM WITH IBUPROFEN AND HIGH-DOSE METHYLPREDNISOLONE [J].
CHYATTE, D ;
RUSCH, N ;
SUNDT, TM .
JOURNAL OF NEUROSURGERY, 1983, 59 (06) :925-932
[4]   CURRENT CONCEPTS - COMPLEMENT IN THE PATHOPHYSIOLOGY OF HUMAN-DISEASE [J].
FRANK, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (24) :1525-1530
[5]   NEW SYNTHETIC INHIBITORS OF CIRBAR, CI ESTERASE, THROMBIN, PLASMIN, KALLIKREIN AND TRYPSIN [J].
FUJII, S ;
HITOMI, Y .
BIOCHIMICA ET BIOPHYSICA ACTA, 1981, 661 (02) :342-345
[6]   Reaction of the meninges to blood [J].
Hammes, EM .
ARCHIVES OF NEUROLOGY AND PSYCHIATRY, 1944, 52 (06) :505-514
[7]  
HANSCH GM, 1984, J IMMUNOL, V133, P2145
[8]   THE TIME COURSE OF INTRACRANIAL PATHOPHYSIOLOGICAL CHANGES FOLLOWING EXPERIMENTAL SUBARACHNOID HEMORRHAGE IN THE RAT [J].
JACKOWSKI, A ;
CROCKARD, A ;
BURNSTOCK, G ;
RUSSELL, RR ;
KRISTEK, F .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1990, 10 (06) :835-849
[9]   PLATELET THROMBOXANE RELEASE AND DELAYED CEREBRAL-ISCHEMIA IN PATIENTS WITH SUBARACHNOID HEMORRHAGE [J].
JUVELA, S ;
HILLBOM, M ;
KASTE, M .
JOURNAL OF NEUROSURGERY, 1991, 74 (03) :386-392
[10]  
KABAT EA, 1961, EXPERIMENTAL IMMUNOC, P149